4
Changes in Ownership
Allogene Therapeutics, Inc. Filed Acc 0001209191-18-055374
President and CEO bought 40,000 shares at $18.00 ($720,000)
- President and CEO acquired 29,946 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
Chang David D · President and CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2018-10-15 | Purchase : show line 1 in the form | +40,000 | $18.00 | $720,000 | 1,995,625 | D |
| 2018-10-15 | Conversion : show line 2 in the form | +29,946 | 1,101,838 | I | ||
| Open-market purchases · 40,000 sh · avg $18.00 · $720,000 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2018-10-15 | Conversion : show line 3 in the form Series A Convertible Preferred Stock | −5,704 | 0 | I |
Loading xslF345X03/doc4.xml…